ECZTRA 6 Phase 3 Randomized Trial Supports Tralokinumab for Adolescent Moderate-to-Severe Atopic Dermatitis
1. Interleukin-13 targeted treatment with tralokinumab was effective and well-tolerated for adolescent moderate-to-severe atopic dermatitis. 2. No new safety signals ...